Guo Zhu, Lu Xiuhua, Carney Paul J, Chang Jessie, Tzeng Wen-Pin, York Ian A, Levine Min Z, Stevens James
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA.
Vaccines (Basel). 2023 Jul 31;11(8):1307. doi: 10.3390/vaccines11081307.
The globular head domain of influenza virus surface protein hemagglutinin (HA1) is the major target of neutralizing antibodies elicited by vaccines. As little as one amino acid substitution in the HA1 can result in an antigenic drift of influenza viruses, indicating the dominance of some epitopes in the binding of HA to polyclonal serum antibodies. Therefore, identifying dominant binding epitopes of HA is critical for selecting seasonal influenza vaccine viruses. In this study, we have developed a biolayer interferometry (BLI)-based assay to determine dominant binding epitopes of the HA1 in antibody response to influenza vaccines using a panel of recombinant HA1 proteins of A(H1N1)pdm09 virus with each carrying a single amino acid substitution. Sera from individuals vaccinated with the 2010-2011 influenza trivalent vaccines were analyzed for their binding to the HA1 panel and hemagglutination inhibition (HI) activity against influenza viruses with cognate mutations. Results revealed an over 50% reduction in the BLI binding of several mutated HA1 compared to the wild type and a strong correlation between dominant residues identified by the BLI and HI assays. Our study demonstrates a method to systemically analyze antibody immunodominance in the humoral response to influenza vaccines.
流感病毒表面蛋白血凝素(HA1)的球状头部结构域是疫苗引发的中和抗体的主要靶点。HA1中只要有一个氨基酸替换就可能导致流感病毒的抗原漂移,这表明某些表位在HA与多克隆血清抗体结合中起主导作用。因此,确定HA的主要结合表位对于选择季节性流感疫苗病毒至关重要。在本研究中,我们开发了一种基于生物层干涉术(BLI)的检测方法,使用一组携带单个氨基酸替换的A(H1N1)pdm09病毒重组HA1蛋白,来确定HA1在流感疫苗抗体反应中的主要结合表位。分析接种2010 - 2011年流感三价疫苗个体的血清与HA1蛋白组的结合情况,以及对具有同源突变的流感病毒的血凝抑制(HI)活性。结果显示,与野生型相比,几种突变的HA1的BLI结合减少了50%以上,并且BLI和HI检测确定的主要残基之间存在强相关性。我们的研究展示了一种系统分析流感疫苗体液反应中抗体免疫优势的方法。